10150370Advancement of novel preclinical models of age-related macular degenerationClosedGrant for R&DInnovate UKMediNect Bioservices is advancing the frontiers of preclinical research in ophthalmology by expanding its capabilities to address critical unmet needs in retinal disease. Our main innovation is an in vivo model of subretinal fibrosis, a devastating end-stage phenotype of age-related macular degeneration (AMD) that leads to irreversible vision loss. Subretinal fibrosis is a significant challenge in AMD, with no effective treatments currently available. Existing therapeutic strategies fail to address the fibrotic processes that underlie the progression of this condition, leaving patients with limited options and a severe decline in quality of life. To tackle this, MediNect is building a comprehensive preclinical offering that combines cutting-edge in vivo and in vitro models to evaluate new therapies for retinal fibrosis. In line with the principles of the 3Rs (Replace, Reduce, Refine), we aim to significantly reduce reliance on animal testing while enhancing the scientific rigour and translational value of our research. Our approach begins with robust 2D in vitro models that replicate cellular fibrotic damage, progressing to advanced 3D tissue models that replicate the complexity of the retinal environment. These models will provide pharmaceutical developers with invaluable tools to screen compounds, optimise therapeutic delivery, and study disease mechanisms in detail that is currently not offered in the industry. Ultimately, our goal is to develop a fully functional 3D model of retinal disease, which could eliminate the need for animal models altogether, while offering insights into disease progression and treatment efficacy. The market need for preclinical solutions in ophthalmology is valued at $800M (Grand View Research, 2023). AMD affects 200 million patients globally (Bright Focus, 2022), with up to 70% of patients developing subretinal fibrosis an endpoint that significantly contributes to blindness and healthcare burden. Developing effective treatments for this condition requires predictive and translationally relevant preclinical models, which MediNect is uniquely positioned to deliver. Through this initiative, MediNect aims to cement its position as a world-leading preclinical research organisation specialising in ophthalmology. The funding will enable us to expand our capabilities, accelerate innovation, and provide pharmaceutical companies with transformative tools to develop effective therapies for retinal diseases. This project not only supports the growth of MediNect but also addresses a pressing global health need, paving the way for better treatments and improved patient outcomes in retinal disease.